These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15304473)

  • 1. Group A streptococcal vaccines.
    Pichichero ME
    JAMA; 2004 Aug; 292(6):738-9. PubMed ID: 15304473
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
    Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
    JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes.
    Morefield G; Touhey G; Lu F; Dunham A; HogenEsch H
    Vaccine; 2014 Jun; 32(30):3810-5. PubMed ID: 24837509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC
    Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract]   [Full Text] [Related]  

  • 5. Current status of group A streptococcal vaccine development.
    Dale JB
    Adv Exp Med Biol; 2008; 609():53-63. PubMed ID: 18193657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
    Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quest for GAS vaccine.
    Pandey M; Good MF
    Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract]   [Full Text] [Related]  

  • 8. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
    Smeesters PR; Dramaix M; Van Melderen L
    Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of Group A streptococcal vaccines: an unmet global health need.
    Sheel M; Moreland NJ; Fraser JD; Carapetis J
    Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress toward a global group a streptococcal vaccine.
    Steer AC; Dale JB; Carapetis JR
    Pediatr Infect Dis J; 2013 Feb; 32(2):180-2. PubMed ID: 23328823
    [No Abstract]   [Full Text] [Related]  

  • 11. Application of the C3-binding motif of streptococcal pyrogenic exotoxin B to protect mice from invasive group a streptococcal infection.
    Kuo CF; Tsao N; Cheng MH; Yang HC; Wang YC; Chen YP; Lin KJ
    PLoS One; 2015; 10(1):e0117268. PubMed ID: 25629609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptococcal vaccines revisited.
    Stollerman GH
    J Lab Clin Med; 1978 Jun; 91(6):872-80. PubMed ID: 77303
    [No Abstract]   [Full Text] [Related]  

  • 13. Group A streptococcus epidemiology and vaccine implications.
    Cohen-Poradosu R; Kasper DL
    Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.
    Pandey M; Sekuloski S; Batzloff MR
    Immunol Cell Biol; 2009 Jul; 87(5):391-9. PubMed ID: 19417770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group A streptococcal vaccines: facts versus fantasy.
    Steer AC; Batzloff MR; Mulholland K; Carapetis JR
    Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
    Good MF; Pandey M; Batzloff MR; Tyrrell GJ
    Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
    Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
    J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein adhesins as vaccine antigens for Group A Streptococcus.
    Raynes JM; Young PG; Proft T; Williamson DA; Baker EN; Moreland NJ
    Pathog Dis; 2018 Mar; 76(2):. PubMed ID: 29718270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
    Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
    Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.